Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 3/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10781336 | 0.87 | SMN1; SMN2 (0.44) | NLRP3ALDH1A1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL4825037 | 0.87 | NLRP3 (0.58) | NLRP3ALDH1A1L3MBTL1PDE4DKMT2A | |
| SCHEMBL23054108 | 0.84 | HTT (0.45) | NLRP3ALDH1A1HTTDHODHKMT2A | |
| SCHEMBL30954548 | 0.82 | HDAC1 (0.48) | ALDH1A1HTTDHODHKMT2ASMN1; SMN2 | |
| SCHEMBL16240385 | 0.82 | HDAC1 (0.48) | ALDH1A1HTTDHODHKMT2ASMN1; SMN2 | |
| SCHEMBL9410531 | 0.81 | PDE4D (0.49) | NLRP3ALDH1A1L3MBTL1PDE4DKMT2A | |
| SCHEMBL19781758 | 0.81 | NLRP3 (0.53) | NLRP3ALDH1A1L3MBTL1PDE4DKMT2A | |
| SCHEMBL23043120 | 0.80 | KMT2A (0.49) | NLRP3ALDH1A1HTTDHODHKMT2A | |
| SCHEMBL20560207 | 0.79 | HTT (0.46) | ALDH1A1HTTDHODHKMT2ATHRB | |
| SCHEMBL20621414 | 0.78 | NLRP3 (0.54) | NLRP3ALDH1A1L3MBTL1PDE4DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | NLRP3 486/4885ALDH1A1 471/4885L3MBTL1 4116/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | NLRP3 486/4885ALDH1A1 471/4885L3MBTL1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.